Literature DB >> 7573305

Improved surgical treatment of familial exudative vitreoretinopathy in children.

L C Glazer1, A Maguire, M S Blumenkranz, M T Trese, W R Green.   

Abstract

PURPOSE: To evaluate current surgical results in patients with familial exudative vitreoretinopathy and study the histologic findings of epiretinal membranes obtained at the time of surgery.
METHODS: We performed phakic pars plana vitrectomy and membrane peeling on five patients (six eyes) with familial exudative vitreoretinopathy, who ranged in age from 18 months to 9 years and had traction retinal detachment. Membranes from two eyes (two patients) were analyzed by light and electron microscopy.
RESULTS: The macula was reattached in all six eyes. Visual acuity improved after surgery in five of the six eyes, with two eyes improving from a preoperative visual acuity of 20/400 to a postoperative visual acuity of 20/25 and 20/60. Electron microscopic analysis of the membranes from two patients disclosed thick fibrocellular fragments with vascular elements and astrocytes.
CONCLUSION: With current surgical techniques, there appears to be improvement in the anatomic reattachment rate and visual outcome in patients with familial exudative vitreoretinopathy. Amblyopia, reproliferation, and vitreous hemorrhage may limit long-term improvement in vision.

Entities:  

Mesh:

Year:  1995        PMID: 7573305     DOI: 10.1016/s0002-9394(14)72661-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  2 in total

1.  Analysis of Predisposing Clinical Features for Worsening Traction After Treatment of Familial Exudative Vitreoretinopathy in Children.

Authors:  G Baker Hubbard; Alexa L Li
Journal:  Am J Ophthalmol       Date:  2020-07-21       Impact factor: 5.258

2.  A white membrane beneath the inner limiting membrane of the retina in a 4-year-old child with ultrastructural evidence: a case report.

Authors:  Wenyi Tang; Ruiping Gu; Ting Zhang; Gezhi Xu
Journal:  BMC Ophthalmol       Date:  2018-03-20       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.